Nebulized salbutamol diminish the blood glucose fluctuation in the treatment of non-oliguric hyperkalemia of premature infants

Saw, Hean-Pat; Chiu, Cheng-Di; Chiu, You-Pen; Ji, Hui-Ru; Chen, Jia-Yuh

doi:10.1016/j.jcma.2018.04.002

Cited by 5 publications

(3 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A clinical trial in healthy individuals demonstrated that receiving 10 mg nebulized albuterol decreased the potassium level by 0.5 mmol/L, which was not observed in the placebo group [ 47 ]. Nebulization with 200 μg/mL albuterol is not only as effective as 10–15 mg glucose and 1 unit of insulin infusion but can avoid vigorous blood glucose fluctuations [ 48 ]. However, the common adverse reactions of beta-2 agonists include anxiety, tachycardia, palpitations, headache, and musculoskeletal tremors [ 49 , 50 ].…”

Section: Recommendations Of Treatment For Hyperkalemiamentioning

confidence: 99%

Recent Progresses in Non-Dialysis Chronic Kidney Disease Patients with Hyperkalemia: Outcomes and Therapeutic Strategies

Tian

Zhou

2023

Medicina

View full text Add to dashboard Cite

Chronic kidney disease (CKD) affects about 10% of the world’s population. Hyperkalemia is a life-threatening complication in patients with CKD, as it is associated with adverse cardiovascular and kidney outcomes. There are still many challenges and questions to address to improve the currently available therapeutic strategies to treat hyperkalemia, such as how to approach the emergency management of hyperkalemia. In recent years, in addition to novel oral potassium binders, great progress has been made in the application of novel kidney protective strategies, such as mineralocorticoid receptor antagonists and sodium–glucose cotransporter 2 inhibitors (SGLT2i) in hyperkalemia therapy. This review will discuss the recent advances from clinical trials in the effective management of hyperkalemia in non-dialysis CKD patients, enhancing the knowledge of physicians and internists concerning these newer agents and providing a helpful reference for clinical practice.

show abstract

Section: Recommendations Of Treatment For Hyperkalemiamentioning

confidence: 99%

Recent Progresses in Non-Dialysis Chronic Kidney Disease Patients with Hyperkalemia: Outcomes and Therapeutic Strategies

Tian

Zhou

2023

Medicina

View full text Add to dashboard Cite

show abstract

“…Potassium-containing intravenous fluids should be avoided in infants with AKI. A study of 40 preterm infants (<36 weeks) suggested the use of nebulised salbutamol may be as effective as insulin/dextrose in infants with non-oliguric hyperkalaemia with less impact on blood glucose ( 108 ).…”

Section: Assessment and Managementmentioning

confidence: 99%

Management of Acute Kidney Injury in Extremely Low Birth Weight Infants

et al. 2022

View full text Add to dashboard Cite

Acute kidney injury (AKI) is a common problem in the neonatal intensive care unit (NICU). Neonates born at <1,000 g (extremely low birth weight, ELBW) are at an increased risk of secondary associated comorbidities such as intrauterine growth restriction, prematurity, volume restriction, ischaemic injury, among others. Studies estimate up to 50% ELBW infants experience at least one episode of AKI during their NICU stay. Although no curative treatment for AKI currently exists, recognition is vital to reduce potential ongoing injury and mitigate long-term consequences of AKI. However, the definition of AKI is imperfect in this population and presents clinical challenges to correct identification, thus contributing to under recognition and reporting. Additionally, the absence of guidelines for the management of AKI in ELBW infants has led to variations in practice. This review summarizes AKI in the ELBW infant and includes suggestions such as close observation of daily fluid balance, review of medications to reduce nephrotoxic exposure, management of electrolytes, maximizing nutrition, and the use of diuretics and/or dialysis when appropriate.

show abstract

“…The vibrating mesh nebulizer results in superior lung deposition of the drug, most likely from smaller residual volume and low operational gas flows ( Table 3 ). 43 …”

Section: Albuterol (Salbutamol)mentioning

confidence: 99%

Inhaled Pharmacotherapy for Neonates: A Narrative Review

Rocha¹

2021

Turk Arch Pediatrics

View full text Add to dashboard Cite

The inhaled route for drug administration in neonates offers several advantages over the systemic routes, since it delivers medications directly to the diseased organ, enabling higher doses locally with less systemic toxicity. Respiratory drugs can be administered in both ventilated and non-ventilated term and preterm infants. This review was carried out using selected literature, with a focus on the most used inhaled pharmacological agents in neonatal care, summarizing, with levels of evidence (LoE), their indications, doses, administration schedules, and main adverse effects. Information is given on several inhaled drugs, namely albuterol, budesonide, ipratropium bromide, sodium cromoglycate, racemic epinephrine, nitric oxide, treprostinil, iloprost, epoprostenol, colistin, rhDNase, hypertonic saline, and calfactant. A summary of the main and most recent published studies on each of these inhaled pharmacological agents is also presented.

show abstract

Nebulized salbutamol diminish the blood glucose fluctuation in the treatment of non-oliguric hyperkalemia of premature infants

Abstract: Salbutamol nebulization is not only as effective as glucose-insulin infusion for treating non-oliguric hyperkalemia in premature infants but can avoid potential side effects such as vigorous blood glucose fluctuations.

Cited by 5 publications

References 36 publications

Recent Progresses in Non-Dialysis Chronic Kidney Disease Patients with Hyperkalemia: Outcomes and Therapeutic Strategies

Recent Progresses in Non-Dialysis Chronic Kidney Disease Patients with Hyperkalemia: Outcomes and Therapeutic Strategies

Management of Acute Kidney Injury in Extremely Low Birth Weight Infants

Inhaled Pharmacotherapy for Neonates: A Narrative Review

Contact Info

Product

Resources

About